Van Cleef Asset Management Inc Increases Stock Holdings in Stryker Co. (NYSE:SYK)

Van Cleef Asset Management Inc raised its stake in Stryker Co. (NYSE:SYK) by 0.6% during the 4th quarter, HoldingsChannel reports. The firm owned 45,226 shares of the medical technology company’s stock after acquiring an additional 251 shares during the period. Stryker accounts for 1.9% of Van Cleef Asset Management Inc’s portfolio, making the stock its 13th biggest position. Van Cleef Asset Management Inc’s holdings in Stryker were worth $13,543,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in shares of Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after buying an additional 61 shares in the last quarter. HBC Financial Services PLLC acquired a new position in Stryker during the fourth quarter worth $37,000. Bourgeon Capital Management LLC acquired a new position in Stryker during the fourth quarter worth $37,000. Operose Advisors LLC raised its holdings in Stryker by 308.6% during the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after purchasing an additional 108 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its holdings in Stryker by 97.1% during the fourth quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock worth $41,000 after purchasing an additional 67 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. In the last 90 days, insiders sold 212,109 shares of company stock worth $72,845,768. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

SYK stock traded up $0.24 on Thursday, reaching $337.09. The company’s stock had a trading volume of 1,615,335 shares, compared to its average volume of 1,286,429. Stryker Co. has a 52 week low of $249.98 and a 52 week high of $361.41. The company has a market capitalization of $128.25 billion, a P/E ratio of 40.86, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89. The firm has a fifty day moving average of $349.39 and a two-hundred day moving average of $314.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the prior year, the company posted $3.00 EPS. As a group, analysts predict that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a dividend of $0.80 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.95%. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Analyst Ratings Changes

A number of research firms have recently weighed in on SYK. TD Cowen boosted their price target on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and boosted their price target for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Roth Mkm boosted their price target on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Finally, Truist Financial lifted their price objective on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $340.67.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.